Bowel Management Systems Market to Witness Widespread Expansion During 2020-2027

Market Research Future (MRFR), in their recently launched report, has asserted that the global bowel management systems market is expected to showcase a steady CAGR of 4.1% over the forecast period. The global bowel management systems market is estimated to reach a market valuation of USD 2.188 billion between the forecast period of 2017-2023. Various factors are attributing to the accelerated growth noted in the global bowel management systems market.

A rapid change in lifestyles of the general public has led to a surge in the intestinal issues such as constipation and fecal incontinence. Advancements in healthcare technology, along with various technological developments in medical devices, has pushed sizeable growth in the bowel management systems market. Further, the rise of the geriatric population, across the globe, has propelled the surging bowel management systems market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6649 

Additionally, the dietary imbalance caused due to the consumption of unhealthy food is also causative of fast-paced growth noted in the global bowel management systems market. However, on the other hand, concerns regarding the discomfort associated with the use of bowel management devices are likely to pose as a hindrance in the ascension of the global bowel management systems market. Also, an inclination towards the adoption of non-invasive and minimally invasive treatments is anticipated to restrain the bowel management systems market from upscaling during the forecast period.

Market Segmentation

The global bowel management systems market is studied for various segments based on products, patient types, end-user, and region. Based on product, the global bowel management systems market is segmented into irrigation systems, nerve modulation devices, and colostomy bags. The colostomy bags segment is expected to hold the biggest share of the global bowel management systems market. On the other hand, the nerve modulation devices (NMD) segment is expected to ascend at the fastest rate during the forecast period.

Based on patient types, the global bowel management systems market is segmented into pediatric patients and adult patients. The adult patients segment is estimated to hold the major share of the global bowel management systems market over the forecast period.

Based on end-users, the global bowel management systems market is studied for the segments of hospitals and ambulatory surgery centers, and home care. The home care segment spearheads the global bowel management systems market.

Detailed Regional Analysis

The bowel management systems market is analyzed for the regional segments of the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas are anticipated to dominate the global bowel management systems market over the forecast period. This can be due to the rapid adoption of technologically advanced healthcare solutions and a high prevalence of intestinal disorders causative of rising adoption of an unhealthy lifestyle and eating habits. Increasing prevalence of the geriatric population and ascending healthcare expenditure are other factors contributing to the heavy ascension of the regional bowel management systems market.

Mounting research activities for the development of comfortable bowel management systems has pushed the bowel management systems market prevalent in Europe. Moreover, faster adoption of advanced technology is encouraging growth in Europe’s bowel management systems market.

Asia Pacific is projected to exhibit the fastest growth rate in the bowel management systems market over the assessment period. This can be owed to the fast-paced development of the healthcare sector in the region. Further, rising awareness of the availability of effective bowel management treatments has contributed to the heavy ascension noted in the regional market over the forecast period. An upscaling in the geriatric population residing in the region has led to a rising need for bowel management systems.  

The Middle East & Africa is expected to showcase slow growth for bowel management systems market over the assessment period. This can be accredited to the lack of awareness and the presence of poor healthcare facilities in the region.

Key Players

The global bowel management systems market boasts the presence of many prominent market players including Medtronic (Ireland), Coloplast (Denmark), 3M (the U.S.), Aquaflush Medical Limited (the U.K.),  Hollister (the U.S.), B. Braun (Germany), Consure Medical (India), C.R. Bard (the U.S.), Cogentix Medical (the U.S.), ConvaTec (the U.K.), Axonics Modulation Technologies (the U.S.), MBH-International A/S (Denmark), Welland Medical limited (the U.K.), Mederi Therapeutics Inc. (the U.S.), and Wellspect HealthCare (Sweden).

Industry Update

August 2019: Axonics Modulation Technologies recently announced the completion of their one-year follow-ups and clinical results from ARTISAN SNM pivotal study conducted under the US FDA. Axonics has developed and is providing Sacral Neuromodulation (SNM) device, on a commercial scale, for the treatment of urinary and bowel dysfunction.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bowel-management-systems-market-6649 

Artificial Neural Network Market – Insights on Upcoming Trends 2027

 Market Dynamics 

An artificial neural network is a form of artificial intelligence which is based on the structure and functions of human neural networks. The artificial neural network software can be used for medical research, drug development, clinical diagnosis of various diseases, and interpretation of clinical imaging techniques, among others.

Key factors driving the growth of the market are the emergence of artificial intelligence, increasing healthcare expenditures by the government in developed regions, and increasing adoption of the artificial neural network in the healthcare sector. Moreover, the increasing prevalence of several chronic diseases globally is likely to contribute to the growth of the artificial neural network. In January 2017, a scientist demonstrated that the IBM Watson for oncology would be a reliable Artificial Intelligence (AI) system for assisting the diagnosis of cancer.

However, slow digitization across emerging regions and reluctance among healthcare professionals to adopt artificial intelligence-based technologies are some factors that can hinder the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6287 

Regional Analysis

The market in the Americas is expected to dominate the global artificial neural network market during the forecast period owing to the well-established healthcare sector, the presence of a large number of companies such as Microsoft Corporation, Intel Corporation, and Google Inc. engaged in the development of neural network technologies, and growing adoption of artificial intelligence in the healthcare sector. The European market is expected to be the second-largest market due to the increasing preference for artificial intelligence among healthcare providers, growing healthcare expenditure, and rising prevalence of chronic diseases. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the least market share of the global artificial neural network market. The market growth in this region can be attributed to growing technological implementations and increasing healthcare expenditures.

Segmentation

The global artificial neural network market has been segmented into type, component, and application.

The market, on the basis of type, has been segmented into feedback artificial neural network, feedforward artificial neural network, and others.

The market, by component, has been segmented into software, services, and platform.

The global artificial neural network market, by application, has been segmented into clinical diagnosis and prognostics, image analysis and interpretation, bioelectric signal analysis and interpretation, drug development, and others.

Global Artificial Neural Network Key Players

Some of the prominent players in the global artificial neural network market are Starmind International AG, Neural Technologies Limited, SwiftKey,  Afiniti, Ward Systems Group, Inc., SAP SE, NeuroDimension, Inc., Alyuda Research, LLC., Google Inc., Neuralware, Qualcomm Technologies, Inc., Intel Corporation, Microsoft Corporation, IBM Corporation, and Oracle Corporation.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/artificial-neural-network-market-6287 

Artificial Eye Market Dynamics, Segments and Supply Demand 2020-2027

 Market Dynamics 

The growing number of people who are blind or partially blind is driving the global artificial eye market. The global artificial eye market is being driven by an increase in the number of people who are blind or partially blind, as well as an aging population. The market is also growing due to the rising prevalence of diseases that affect vision, technological advancements, and the prevalence of diseases such as diabetes. The market's development has been slowed by the high cost of care and the availability of low-cost alternatives. Over the forecast period, the artificial eye market will be driven by rising cases of ophthalmic defects and injuries. The market for artificial eyes is expected to rise as technology advances.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/985 

Furthermore, there are a variety of insurance plans that make surgery accessible to a wide range of people. To ease the financial strain, the United States and several other countries have compensation coverage for medical care through different insurance schemes. Government campaigns to help patients all over the world facilitate reimbursement programs. As a result, demand for artificial eyes will rise over the forecast period. Furthermore, rising medical tourism for low-cost artificial eye implantation procedures and technological advancements in artificial eye advancement are major factors driving market growth. However, the high cost of artificial eyes, as well as the high cost of implantation procedures related to artificial eyes, could stifle industry development. 

Segmental Analysis 

Global artificial eye market is segmented on the basis of type, Non-integrated implants, Integrated implants. Integrated implants are further segmented into hydroxyapatite, porous polyethylene, bioceramic, conical orbital implant and other. On the basis of technology, they are segmented into electronic and mechanical and on the basis of end user, the market is segmented into hospitals, ophthalmology clinics and others. 

Regional Analysis 

On regional basis, global artificial eye market is segmented into four major regions namely Americas, Europe, Asia Pacific and Middle East and Africa.  

Because of its large geriatric population and growing number of people suffering from vision impairment, America leads the global artificial eye industry. According to the American Academy of Ophthalmology, more than a quarter of the population in the United States has a minor or major visual complication, and this figure is steadily increasing due to the growing diabetic population. Because of increased product innovation, increased presence of leading players, increased favorable reimbursement policies, and high acceptance of artificial eye surgeries in this area, North America dominates the artificial eye market. Due to the presence of qualified professionals, highly developed healthcare infrastructure, technological advances, and the presence of large market players in the region, the United States dominates the global artificial eye market. In addition, the country's large healthcare expenditures would drive business growth.

Because of increased construction activities, increased healthcare spending per person, and government support in this area, Europe has the second largest artificial eye market in terms of growth. The European artificial eye market will continue to be driven by rising demand for custom-made ocular prostheses and the the prevalence of ophthalmic diseases.

The artificial eye market in Asia Pacific is rising at the fastest pace. Because of their well-developed healthcare sectors and high health-care spending, Japan and Australia are the leading contributors to the industry. Because of technological advances, the disposable incomes, and the innovations in the healthcare system, Japan is expected to see substantial growth in the artificial eye market during the study era. Artificial eye demand will be boosted by the factors listed above.

Owing to a lack of medical services and weak economic and political conditions, the Middle East and Africa has the smallest market share. The artificial eye market in the Middle East and Africa is dominated by Saudi Arabia, the United Arab Emirates, and Kuwait.

Competitive Analysis 

Advanced Artificial Eye (US), The National Artificial Eye Services (NHS) (UK), Marie Allen Ocularist Ltd (Canada), COS-MEDIC PTY LTD (Australia), Retina Implant AG (Germany), Second Sight (US), Pixium Vision (France), Ericksons Custom Made Artificial Eye (Canada), International Prosthetic Eye Center (India) are among the major market players. The global artificial eye market is fragmented, with many small players competing for market share with a few large players. Partnerships, mergers, acquisitions, and the introduction of new products are some of the major strategic steps taken by market leaders to broaden their company product range.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/artificial-eye-market-985 

Global Chinese Fibromyalgia Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

 Fibromyalgia syndrome co-exists with other painful conditions, such as migraine and other types of headaches, temporomandibular joint disorders, irritable bowel syndrome (IBS), and interstitial cystitis. The treatment of fibromyalgia includes both targeted and symptomatic approach. Till date, there are only three FDA approved drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli Lilly and Company), and Savella (Allergan plc). However, there are few other drugs prescribed by physicians to control the symptoms of fibromyalgia such as pain relievers, muscle relaxants, and traditional Chinese medicine.

Growing geriatric population, increasing cases of rheumatic diseases, growing awareness among the population, and rising incidences of traumatic stress and road accidents are the key factors driving the Chinese fibromyalgia market. According to a study published in the Arthritis Care & Research journal in 2017, fibromyalgia and related symptoms worsen the functional status of individuals with rheumatoid arthritis. Around 15%-30% of patients with rheumatic disorders have co-morbid fibromyalgia syndrome.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5630 

However, difficulty in diagnosis of the disease, and stringent FDA regulations may hinder the growth of the market to an extent. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than the general population.

The Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630 

Hematocrit Test Market Insights Analysis 2020-2027

 Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5553 

The Global Hematocrit Test Market is expected to Grow at a CAGR of 4.5% during the forecast period.

Regional Analysis:

The Americas hold the largest market share in the hematocrit test due to increasing demand for technologically advanced hematology analyzers and test kits. Additionally, the presence of major market players also influences the growth of the market in the U.S. followed by Canada. Kidney disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. Prevalence of cardiovascular disease and kidney diseases further accelerate the market growth. In South America, the market exhibits better growth opportunities due to the development of healthcare industry in recent years.

In Europe, the prevalence of diabetes, a major risk factor for heart disease is increasing in major economies such as Germany, thereby signifying the need for diagnostics services. Germany, France, and the U.K are the major contributors to the market growth in Europe with key players focusing on product differentiation and quality. Furthermore, the development of medical device industry and increasing awareness about early diagnosis of chronic diseases such as cancer is driving the market growth. Moreover, extensive research and development activities in the field of hematology, and the emergence of new market players in medical device industry determine the market growth. 

In the Asia Pacific region, Japan, China, and India are the largest contributors to the market growth.  Increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, and kidney disease are the major driver for the market growth. The rapid growth of healthcare market and extensive demand for diagnostic services further fuel the growth of the market.

In the Middle East & Africa, the United Arab Emirates, Saudi Arabia, and Kuwait hold the least share of the global market due to lack of knowledge about diagnostic tests for chronic diseases and low technologically advanced devices. Whereas, the African region is expected to witness moderate growth in the market.

Segmentation:

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of the product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of the indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Key Players:

Some of key the players in the market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553 

Parathyroid Disorders Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

 Parathyroid hormone plays a significant role in regulating the metabolism of calcium, phosphate, and Vitamin D. The hyperparathyroidism, and hypoparathyroidism are the two most common parathyroid disorders.

A number of factors such as growing geriatric population, rising prevalence of parathyroid disorders, increasing government assistance, rising healthcare expenditure, improving regulatory framework, and rising funding and reimbursements are propelling the growth of the global parathyroid disorders market.

However, challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market.

It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5451 

Regional Analysis:

The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.

The Asia Pacific is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.

Segmentation

The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further sub-segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.

On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.

On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Key Players

Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451 

Obstructive Lung Disease Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of  the global obstructive lung disease market. The market is driven by the growing COPD and asthmatic patient population, as well as the FDA approval for novel products and its wide acceptance. Increasing government initiatives to control COPD and asthma further, fuel the growth of this market.

Due to the rising instances of COPD across the globe, it has become indispensable for organizations to offer promising healthcare solutions to reduce health complications. With a considerable part of population being infected by the disease, renowned COPD drug manufacturers are facing the need to reduce inflammation and improve patient health outcomes.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5367 

Regional Analysis

Global obstructive lung disease consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

North America together dominates the global asthma and COPD market followed by the European market. Rising prevalence of asthma and COPD due to pollution, changing lifestyle, and the entry of generic and novel therapies in the market.

Asia Pacific is anticipated to be the fastest growing market over the forecast period. Emerging economies such India, China due to industrialization, demographic changes, and urbanization are witnessing increased levels of pollution, thus favoring the rising prevalence of asthma and COPD population.

Segmentation

The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.

On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others 

On the basis of product type, market is segmented into inhalers, and nebulizers. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs). Moreover, nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers

On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.

On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Key Players

Some of key the players in the global obstructive lung disease market are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.),  Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/obstructive-lung-disease-market-5367